News & Events
-
June 28, 2022
C-Path Welcomes Parexel
C-Path is proud to welcome Parexel as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Comprised of 17 firms that provide electronic data collection technologies and services for capturing patient-reported outcome and other clinical outcome assessment data in clinical trials, eCOA Consortium members collaborate in a pre-competitive environment to support and conduct novel research, design... -
June 24, 2022
The Critical Path for Parkinson’s Consortium Welcomes ESCAPE Bio
C-Path’s Critical Path for Parkinson’s Consortium is thrilled to welcome its newest member, ESCAPE Bio, a clinical-stage company developing novel, precisely targeted therapies for genetic neurodegenerative diseases. We applaud ESCAPE Bio for their willingness to share data, consistent with CPP’s open science strategy for advancing drug development tools for Parkinson’s disease trials. -
June 22, 2022
C-Path Receives DIA 2022 Americas Inspire Award for Outstanding Contribution to Health
C-Path is pleased to announce it has received the DIA 2022 Americas Inspire Award for Outstanding Contribution to Health. This prestigious honor is conferred upon an individual, group or organization that has made significant and innovative contributions to advancing global health.
-
June 15, 2022
View Now | Using Ontologies to Standardize Rare Disease Data Collection presented by Monarch Initiative
This webinar will provide an overview of biomedical ontologies and demonstrate how they can be used for standardizing and integrating data and downstream analyses. In addition, we will discuss why you should contribute to ontology development efforts and how to do it. The Monarch Initiative is an integrative data and analytic platform connecting phenotypes to... -
June 9, 2022
C-Path Launches Unique Translational Therapeutics Accelerator with Support from Cottrell Foundation
C-Path today announced it has been awarded a grant from the Frederick Gardner Cottrell Foundation, a non-profit organization established by Research Corporation Technologies, Inc. (RCT) that provides financial support for scientific research and educational programs, to create the C-Path Translational Therapeutics Accelerator (TRxA). The accelerator is a unique, global effort focused on supporting academic scientists in defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients.